Halder Venture Limited Announces Postal Ballot for Capital Increase and Convertible Warrants Issue
Halder Venture Limited has issued a postal ballot notice for two key corporate actions. The company seeks to increase authorized share capital from Rs. 13.42 crore to Rs. 18.42 crore and issue 7,93,650 convertible warrants at Rs. 315 per warrant to raise Rs. 25 crore from P.K. Bio Link Pvt. Ltd. E-voting runs from March 31 to April 29, 2026, with results by May 1, 2026.

*this image is generated using AI for illustrative purposes only.
Halder Venture Limited has announced a postal ballot notice seeking shareholder approval for significant corporate restructuring initiatives. The company has proposed two key resolutions that will enhance its capital structure and funding capabilities.
Authorized Share Capital Enhancement
The company seeks approval to increase its authorized share capital substantially. The proposed enhancement involves expanding the capital base to accommodate future growth and conversion requirements.
| Parameter: | Current Structure | Proposed Structure |
|---|---|---|
| Authorized Capital: | Rs. 13,42,50,000 | Rs. 18,42,50,000 |
| Number of Shares: | 1,34,25,000 | 1,84,25,000 |
| Additional Shares: | - | 50,00,000 |
| Face Value: | Rs. 10 per share | Rs. 10 per share |
The increase in authorized share capital requires alteration to Clause V of the company's Memorandum of Association. This expansion will provide adequate headroom for the proposed convertible warrants and future capital requirements.
Convertible Warrants Issuance
The company proposes to issue convertible warrants on a preferential basis to non-promoter entities. The warrants will provide holders the right to convert into equity shares within a specified timeframe.
| Details: | Specifications |
|---|---|
| Number of Warrants: | 7,93,650 |
| Issue Price: | Rs. 315 per warrant |
| Premium: | Rs. 305 per warrant |
| Total Amount: | Rs. 24,99,99,750 |
| Allottee: | P.K. Bio Link Pvt. Ltd. |
| Conversion Period: | 18 months from allotment |
Pricing and Valuation Framework
Since the company's equity shares are infrequently traded, the pricing follows SEBI ICDR Regulation 165 requirements. An independent registered valuer, CA Sanjay Jhajharia, conducted the valuation assessment.
| Valuation Parameter: | Amount |
|---|---|
| Minimum Price (Valuation Report): | Rs. 314.79 per share |
| Approved Issue Price: | Rs. 315 per share |
| Payment at Allotment: | 25% of issue price |
| Balance Payment: | 75% at conversion |
Fund Utilization Strategy
The company plans to deploy the raised funds across two primary objectives, with equal allocation for each purpose.
| Purpose: | Allocation | Timeline |
|---|---|---|
| Capital Expansion: | Rs. 12,49,99,875 | Within 6 months |
| Working Capital: | Rs. 12,49,99,875 | Within 6 months |
| Total: | Rs. 24,99,99,750 | - |
The capital expansion funds will support business operations expansion, network strengthening, and strategic investments. Working capital augmentation will improve the company's overall financial health and support general corporate purposes.
Shareholding Impact Analysis
The preferential issue will result in shareholding pattern changes, with P.K. Bio Link Pvt. Ltd. acquiring a significant stake upon full conversion.
| Shareholding Category: | Pre-Issue (%) | Post-Issue (%) |
|---|---|---|
| Promoter & Promoter Group: | 73.70% | 69.28% |
| Public Shareholding: | 26.30% | 30.72% |
| P.K. Bio Link Pvt. Ltd.: | 0% | 5.99% |
The ultimate beneficial owners of P.K. Bio Link Pvt. Ltd. are Pronoy Bhattacharyya and Pritikona Bhattacharya. The transaction will not result in any change of control or management.
Voting and Timeline Details
The postal ballot process follows electronic voting procedures, with specific timelines established for shareholder participation.
| Timeline Parameter: | Date/Period |
|---|---|
| Record Date: | March 27, 2026 |
| E-voting Commencement: | March 31, 2026 (10:00 AM) |
| E-voting Conclusion: | April 29, 2026 (5:00 PM) |
| Results Declaration: | By May 1, 2026 |
| Warrant Allotment: | Within 15 days of approval |
Mr. Manoj Prasad Shaw, Practicing Company Secretary, has been appointed as the scrutinizer for the e-voting process. The company will conduct the entire voting process electronically, with notices sent only to shareholders with registered email addresses.
The resolutions require different approval thresholds - the capital increase needs ordinary resolution approval, while the convertible warrants issuance requires special resolution approval from shareholders.
Historical Stock Returns for Halder Venture
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.18% | +0.40% | +1.10% | -7.11% | -7.11% | -7.11% |
How will the significant capital infusion of Rs. 25 crores impact Halder Venture's competitive position and market expansion plans in their industry sector?
What strategic synergies might emerge from P.K. Bio Link's 5.99% stake acquisition, given the biotech connection suggested by their company name?
Will the improved public shareholding ratio of 30.72% make Halder Venture more attractive to institutional investors and improve stock liquidity?


































